{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mechlorethamine&page=49", "query": { "intervention": "Mechlorethamine", "page": 49 }, "page_size": 10 }, "pagination": { "page": 49, "page_size": 10, "total_count": 3022, "total_pages": 303, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mechlorethamine&page=50&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mechlorethamine&page=48&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T17:28:16.739Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01421017", "title": "Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Metastatic Breast Cancer", "Recurrent Breast Cancer" ], "interventions": [ { "name": "Radiation", "type": "RADIATION" }, { "name": "Imiquimod", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 31, "start_date": "2011-08-19", "completion_date": "2016-08-06", "has_results": true, "last_update_posted_date": "2021-11-18", "last_synced_at": "2026-11-11T17:28:16.739Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01421017" }, { "nct_id": "NCT06112379", "title": "A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1902, "start_date": "2023-11-14", "completion_date": "2032-09-23", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-11-11T17:28:16.739Z", "location_count": 58, "location_summary": "Daphne, Alabama • Prescott, Arizona • Jonesboro, Arkansas + 53 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Prescott", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06112379" }, { "nct_id": "NCT00006260", "title": "Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 36, "start_date": "1997-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-06-11", "last_synced_at": "2026-11-11T17:28:16.739Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006260" }, { "nct_id": "NCT01074060", "title": "Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Multiple Myeloma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Multiple Myeloma" ], "interventions": [ { "name": "plerixafor", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 18, "start_date": "2010-04", "completion_date": "2013-02", "has_results": false, "last_update_posted_date": "2013-02-15", "last_synced_at": "2026-11-11T17:28:16.739Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01074060" }, { "nct_id": "NCT00594308", "title": "In-Vivo Activated T-Cell Depletion to Prevent GVHD", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Myelogenous Leukemia", "Acute Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Chronic Lymphocytic Leukemia", "Myelodysplasia", "Lymphoma, Non-Hodgkin's", "Mantle-Cell Lymphoma", "Hodgkin's Disease", "Multiple Myeloma", "Myelofibrosis" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Basiliximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 10, "start_date": "2007-10", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-10-06", "last_synced_at": "2026-11-11T17:28:16.739Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00594308" }, { "nct_id": "NCT05436418", "title": "The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Peripheral Blood Stem Cell Transplantation", "Hematopoietic Stem Cell Transplantation" ], "interventions": [ { "name": "Melphalan", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI)", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mycophenolate Mofeti", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Allogeneic HSCT", "type": "PROCEDURE" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "12 Years to 120 Years" }, "enrollment_count": 260, "start_date": "2022-11-18", "completion_date": "2028-06-25", "has_results": false, "last_update_posted_date": "2026-11-10", "last_synced_at": "2026-11-11T17:28:16.739Z", "location_count": 2, "location_summary": "Duarte, California • Bethesda, Maryland", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05436418" }, { "nct_id": "NCT05972720", "title": "A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer", "Relapsed/Refractory Large B-cell Lymphoma (LBCL)" ], "interventions": [ { "name": "Fludarabine (Conditional therapy)", "type": "DRUG" }, { "name": "Cyclophosphamide Monohydrate (Conditional therapy)", "type": "DRUG" }, { "name": "firi-cel (Experimental drug)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CARGO Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2023-08-01", "completion_date": "2025-04-04", "has_results": false, "last_update_posted_date": "2025-05-15", "last_synced_at": "2026-11-11T17:28:16.739Z", "location_count": 31, "location_summary": "Little Rock, Arkansas • Duarte, California • Los Angeles, California + 24 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05972720" }, { "nct_id": "NCT01967823", "title": "T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Meningioma", "Breast Cancer", "Non-Small Cell Lung Cancer", "Hepatocellular Cancer" ], "interventions": [ { "name": "Anti-NY ESO-1 mTCR PBL", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "15 Years to 70 Years" }, "enrollment_count": 11, "start_date": "2013-10-24", "completion_date": "2020-04-06", "has_results": true, "last_update_posted_date": "2021-03-24", "last_synced_at": "2026-11-11T17:28:16.739Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01967823" }, { "nct_id": "NCT00400946", "title": "05-001: Treatment of Acute Lymphoblastic Leukemia in Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Drug/Agent Toxicity by Tissue/Organ", "Leukemia" ], "interventions": [ { "name": "asparaginase", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "dexrazoxane hydrochloride", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "mercaptopurine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "pegaspargase", "type": "DRUG" }, { "name": "prednisolone", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 800, "start_date": "2005-04", "completion_date": "2019-06", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-11-11T17:28:16.739Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Rochester, New York + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT00400946" }, { "nct_id": "NCT01342289", "title": "Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin's Lymphoma", "Leukemia", "Myelodysplastic Syndrome(MDS)", "Multiple Myeloma", "Non Hodgkin's Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Total body irradiation", "type": "RADIATION" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Tacrolimus 60", "type": "DRUG" }, { "name": "Tacrolimus 90", "type": "DRUG" }, { "name": "Tacrolimus 120", "type": "DRUG" }, { "name": "Bone marrow transplant", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "75 Years", "sex": "ALL", "summary": "6 Months to 75 Years" }, "enrollment_count": 127, "start_date": "2011-08", "completion_date": "2018-03", "has_results": false, "last_update_posted_date": "2018-10-17", "last_synced_at": "2026-11-11T17:28:16.739Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01342289" } ] }